Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence Novo Nordisk A/S Fri, Jan 17, 2025, 7:11 AM 5 min read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback